Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%

MT Newswires Live

08-04

Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.

Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.

The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.

Its shares fell 14% in recent trading on Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556877445"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556877445\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2556877445?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 12:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556877445","market":"sh","top_or_hot":-1,"title":"Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CHM.AU\">Chimeric Therapeutics</a> (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.</p><p>Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.</p><p>The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.</p><p>Its shares fell 14% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-04 12:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CHM.AU\">Chimeric Therapeutics</a> (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.</p><p>Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.</p><p>The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.</p><p>Its shares fell 14% in recent trading on Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2556877445","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556877445","pubTimestamp":1754283189,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chimeric Therapeutics  said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","LENZ":"Therapeutics","BK4007":"制药","CHM.AU":"CHIMERIC THERAPEUTICS LTD","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Chimeric Therapeutics称肿瘤候选治疗研究进展至第二剂量水平，股价下跌14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHM.AU":0.9,"LENZ":1},"content_text":"Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}